Columbia study links halted neurogenesis to depression, opening new treatment pathways

The brain manufactures most of its roughly 100 billion neurons before birth, but a steady, quiet production line continues in one small region of the adult brain—the hippocampus—and researchers at Columbia University have just shown that this production line grinds to a halt in people with major depression. The finding, published this month, is the first direct evidence that neurogenesis stalls in depressed adults, and it points toward a fundamentally different way of thinking about what depression actually is.

For decades, psychiatry treated depression as a simple shortage of serotonin, a chemical messenger in the brain. But Maura Dupont, a professor of psychiatry who led the Columbia research, describes a more complex picture: depression emerges when neurons lose their capacity to adapt. "Without the ability to create new neurons, people with depression may not have the resilience to effectively adapt to the environment," she explains. The hippocampus, a seahorse-shaped structure tucked deep in the brain, is where this adaptation matters most. It governs episodic memory—the ability to recall specific events—and emotional responses to the world around us. It is also one of the few places in the adult brain where new neurons are born.

The hippocampus performs a critical function called pattern separation: it allows us to distinguish between similar but different memories and to keep the emotional weight of past events separate from present ones. Imagine sitting down to lunch with a friend who seems withdrawn and quiet. With healthy pattern separation, you file this as a single, distinct memory. But when pattern separation breaks down, this lunch blurs together with every other time you felt rejected, and you conclude: "She's upset with me." Dupont sees this pattern constantly in her patients—a tendency to retrieve only negative information from memory, to interpret ambiguous moments as confirmation of rejection or failure. The new neurons born in the hippocampus appear to be essential for keeping these memories distinct. They are unusually responsive to new experiences and can be woven into fresh memory circuits more easily than older neurons, allowing new information to be stored separately from the old.

To understand what goes wrong in depression, the Columbia team examined an extraordinary dataset: nearly half a million individual brain cells collected from depressed patients and healthy controls, all examined shortly after death. Using cutting-edge techniques, they recorded the activity of every gene in each cell and detected whether proteins had been altered. The picture that emerged was one of widespread dysfunction. Genes involved in creating new neural connections showed abnormal activity. Genes responsible for energy production were dysregulated. The trisynaptic circuit—the hippocampus's primary pathway for storing emotional memories—displayed signs of inflammation and cellular stress. Some of the altered genes carry genetic variants already linked to depression in large population studies. Others were affected by epigenetic changes, molecular dimmer switches controlled by life experience: stress, learning, aging, exposure to chemicals.

What struck Dupont most was the sheer diversity of molecular disruptions. "The wide range of effects we found could reflect different pathogenetic mechanisms, perhaps indicating that depression is not just one disease," she says. This observation opens a new door. For decades, cancer treatment has moved away from classifying tumors by location and toward classifying them by their molecular features—a shift that has led to far more effective, targeted therapies. Dupont and her colleagues propose doing the same for depression. Instead of treating all depression as a single condition, psychiatry could reclassify it based on the specific molecular signatures present in each patient's brain. A person whose depression stems primarily from halted neurogenesis might benefit from a therapy designed to restart that process. Someone whose depression involves primarily inflammatory changes might need a different approach entirely.

The research does not yet provide a complete map of how these molecular changes cause depression in humans, and turning neurogenesis back on remains theoretical. But Dupont is clear about what the work suggests: "Turning neurogenesis back on may be a way to treat depression in some people by rewiring their hippocampus circuit." The study represents a shift from asking what depression is—a serotonin problem, a cognitive distortion, a life circumstance—to asking what depression looks like at the cellular level. That shift, if it holds, could reshape how psychiatry develops and prescribes treatment.